NPM1:

Mingyue Zhao1, Mingyue Liao1, Robert Peter Gale1,2

  • 1Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing 100044, China.

Biomedicines
|January 8, 2025
PubMed
概括

在患有正常细胞遗传 (CN-AML) 和NPM1突变的急性髓性白血病中,MRD状态,DNMT3A,FLT3-ITD和DDX11突变预测复发风险. 造血干细胞移植有利于高风险患者,改善无白血病的生存率.